ASH 2018 | MRD highlights in myeloma from ASH 2018

VJHemOnc is committed to improving our service to you

Ola Landgren

Ola Landgren, MD, PhD, of the Memorial Sloan Kettering Cancer Center, NY, gives his insight into the measurable residual disease (MRD) data from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter